Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
NEW YORK and LONDON, July 28, 2022 (GLOBE NEWSWIRE) -- Akari…
Rentschler Biopharma and XL-protein demonstrate efficient production of a hyperactive PASylated DNase I with extended half-life
Hyperactive DNase I modified with XL-protein’s PASylation®…
XL-protein announces the Avi-PA(S)™ MAb platform to boost the preclinical and clinical development of therapies using its PASylation® technology
FREISING, GERMANY, July 12, 2021 – XL-protein GmbH, a German…